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a  b  s  t  r  a  c  t
Chronic periaortitis (CP) is an umbrella term used to describe a group of nosologi-
cally allied conditions that include idiopathic retroperitoneal ﬁbrosis (Ormond’s disease),
inﬂammatory abdominal aortic aneurysm, and perianeurysmal retroperitoneal ﬁbrosis.
Retroperitoneal ﬁbrosis encompasses a range of diseases characterized by the presence of
a  ﬁbro-inﬂammatory tissue, which usually surrounds the abdominal aorta and the iliac
arteries and extends into the retroperitoneum to envelop neighboring structures-ureters.
Retroperitoneal ﬁbrosis is generally idiopathic, but can also be secondary to the use of cer-
tain  drugs, malignant diseases, infections, and surgery. Here we describe a 5 years follow-up
(2006–2011) of 5 patients admitted to our hospital with symptoms, laboratory, imaging and
pathologic ﬁnding compatible with retroperitoneal ﬁbrosis. We  review our clinical course of
our  patient with respect to the literature.
© 2014 Elsevier Editora Ltda. All rights reserved.
Fibrose  retroperitoneal:  série  de  cinco  casos  e  revisão  da  literatura
alavras-chave:
ibrose retroperitoneal
rednisona
r  e  s  u  m  o
Periaortite crônica (PC) é um termo genérico usado para descrever um grupo de condic¸ões
nosologicamente ligadas que incluem a ﬁbrose idiopática retroperitoneal (doenc¸a de
Ormond), o aneurisma da aorta abdominal inﬂamatório e a ﬁbrose retroperitoneal peri-
nsuﬁciência renal
amoxifeno
gG4
aneurismática. O termo ﬁbrose retroperitoneal engloba uma  gama de doenc¸as que se
caracterizam pela presenc¸a de um tecido ﬁbroinﬂamatório que geralmente envolve a
aorta abdominal e as artérias ilíacas, se estende ao retroperitôneo e envolve estruturas
ureterais vizinhas. A ﬁbrose retroperitoneal geralmente é idiopática, mas  pode também sersecundária ao uso de determinados fármacos, doenc¸as malignas, infecc¸ões e cirurgia. Este
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estudo descreve o seguimento por cinco anos (2006–2011) de cinco pacientes internados em
nosso hospital que apresentavam sintomas e achados laboratoriais, de imagem e patológi-
cos  compatíveis com a ﬁbrose retroperitoneal. Revisou-se a evoluc¸ão clínica dos pacientes,
que foi comparada com os achados da literatura.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Chronic periaortitis encompasses a group of rare abdom-
inal aorta diseases, including idiopathic (nonaneurysmal)
retroperitoneal ﬁbrosis, inﬂammatory abdominal aortic
aneurysm (IAAA), and perianeurysmal retroperitoneal
ﬁbrosis.1 Some cases involve the thoracic aorta, leading
to mediastinal ﬁbrosis. The idiopathic form accounts for
over 70% of cases of retroperitoneal ﬁbrosis.2 According
to a Finnish study, the estimated incidence of idiopathic
retroperitoneal ﬁbrosis is 0.1 per 100,000 person-years.3 Men
are affected twice to three times more  often than women, the
mean age at presentation is 50–60 years, although reports of
the condition in children and older adults are not uncommon.
This report reviews the literature and describes clinical and
laboratory characteristics, treatment, and outcome of a series
of patients with retroperitoneal ﬁbrosis.
Results
Five patients with retroperitoneal ﬁbrosis were identi-
ﬁed reviewing all rheumatology clinic inpatients records
(2006–2011). The mean (±SD) age was 62.6 ± 5.7 years and
mean (±SD) duration of disease at diagnosis was 3.2 ± 2.16
years. Abdominal and groin pain were the most common clin-
ical manifestations (all patients).
All patients had normocytic anemia and a high C-reactive
protein (CRP) and ESR levels. Three patients were found to
have renal failure. Treatment in all cases consisted of steroids
and tamoxifen. One patient did not improve after treatment,
two patients had partial response, and two patients had full
response (complete remission).
Case  reports
Patient  1
A 64-year-old man  with a history of dyslipidemia presented
with chief complaint of groin pain during the preceding
two months. Physical examination was normal, labora-
tory tests revealed elevated ESR (101 mm/h), mild anemia
with hemoglobin of 11.6 g/dL, and mildly elevated creatinine
(1.29 mg/dL). Anti-nuclear antibody (ANA) titer was negative.
Imaging included a computed tomography (CT) scan, which
showed bilateral moderate hydronephrosis and a mass sur-
rounding the abdominal aorta from the level of the renal
arteries through the iliac bifurcation. The patient underwent
bilateral ureterolysis and omentopexy. Biopsy of the retroperi-
toneal mass disclosed collagenous tissue with inﬂammatorycells, compatible with retroperitoneal ﬁbrosis. The patient was
ﬁrst prescribed prednisone 1 mg/kg/day with tapering therapy
down for three months then maintenance therapy with aza-
thioprine 2 mg/kg/day and tamoxifen 20 mg bid. At a 6-month
follow-up, an increment in the retroperitoneal process was
noted and the dose of azathioprine was increased. Repeated
CT scan one year later revealed a stable retroperitoneal lesion.
The patient continued tamoxifen and azathioprine.
Patient  2
A 55-year-old man, a smoker and with a history of diabetes
mellitus type 2, presented with abdominal pain and weight
loss during the preceding 6 months. Physical examination
was remarkable for abdominal tenderness. Laboratory tests
revealed elevated inﬂammatory markers (CRP 138 mg/L, ESR
77 mm/h), mild anemia and normal creatinine. A CT scan,
revealed hard tissue surrounding the abdominal aorta with
hydronephrosis, and signs of atherosclerosis within the large
arteries. The biopsy revealed ﬁbrous tissue and inﬂammatory
cells.
Treatment with high-dose steroids (1 g methylprednisolone
for 3 days) and cyclophosphamide (500–1000 mg/m2 IV
monthly for 6 doses) led to resolution of the symptoms. There-
after, the patient was prescribed tamoxifen and azathioprine
2 mg/kg/day. Under treatment, repeated imaging of magnetic
resonance (MR) angiography study, one year later at follow up,
disclosed minor tissue surrounding the aorta and inﬂamma-
tory markers normalized. Treatment with cyclophosphamide
was stopped after 6 months and the patient continued tamox-
ifen and azathioprine.
Patient  3
A 57 year-old man  with a 3 year history of Etanercept treated
sacroiliitis presented with pelvic pain and burning sensa-
tion in the groin. Physical examination was positive for
bilateral ﬂank tenderness, laboratory tests revealed elevated
inﬂammatory markers (CRP 126 mg/L, ESR 113 mm/h), mild
anemia with hemoglobin of 11.5 g/dL, and mildly elevated
creatinine of 1.28 mg/dL. ANA was negative. IgG4 isotype
level was elevated (243 mg/dL; normal 1–112). A CT scan,
revealed a retroperitoneal mass encompassing the inferior
vena cava and abdominal aorta with hydronephrosis. The
sacroiliac joints appeared normal. Laparoscopic biopsy dis-
closed ﬁbrotic tissue with chronic inﬂammatory aggregation
and a few macrophages. Treatment consisted of prednisone
60 mg qd and tamoxifen 20 mg  bid. Etanercept was discontin-
ued. Repeated CT scan at follow up, one year later, showed
marked regression of the retroperitoneal mass. Prednisone
was tapered down and the patient continues tamoxifen only.
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atient  4
 59 year-old woman with history of hypothyroidism was
ospitalized for abdominal pain and evidence of bilateral
ydronephrosis on abdominal ultrasound study. Physical
xamination was remarkable for diffuse abdominal tender-
ess with no rebound or peritoneal signs. Laboratory tests
evealed elevated creatinine level of 2.4 mg/dL with ele-
ated inﬂammatory markers (CRP 57 mg/L), and anemia with
emoglobin level of 9.5 g/dL. Imaging during hospitalization
ncluded positron emission tomography PET-CT scan, which
evealed ﬁbrotic tissue surrounding the abdominal aorta at the
evel of L3 to the iliac bifurcation. The patient underwent bilat-
ral robotic ureterolysis followed by administration of pred-
isone 60 mg/day. No biopsy of the lesion was performed, and
reatment was initiated on clinical and radiological grounds.
reatinine level at the last follow-up (2 years later) was greatly
mproved (1.26 mg/dL). Prednisone was tapered down and cur-
ently the patient is under no treatment, due to uncontrolled
lucose level under prednisone treatment. Repeated PET-CT
maging showed no evidence of the retroperitoneal mass.
atient  5
 57-year-old woman with a history of dyslipidemia presented
ith the chief complaint of groin pain and general weakness.
hysical test was normal, laboratory tests revealed elevated
nﬂammatory markers (ESR105 mm/h, CRP 57 mg/L), normal
enal function with creatinine of 0.9 mg/dL. ANA titer was
ositive (1:160) with Homogenous (diffuse) pattern. Imaging
ncluded PET-CT uptake, which showed a mass surrounding
he abdominal aorta from the level of the superior mesenteric
rtery through the iliac bifurcation without hydronephrosis.
he patient was diagnosed with retroperitoneal ﬁbrosis and
reated with prednisone 60 mg/day and tamoxifen 20 mg  bid.
t one-year follow-up, symptoms resolved, inﬂammatory
arkers normalized and repeated PET-CT imaging 2 years
ater showed no evidence of the retroperitoneal mass. Pred-
isone was tapered down to 5 mg/d and tamoxifen continued.
iscussion
etroperitoneal ﬁbrosis can involve any organ proximate to
he retroperitoneum. Ureteral obstruction occurs in up to
0–100% of cases.3 Intestinal or biliary-pancreatic involve-
ent, lower-extremity venous obstruction, aortic or branch
rterial compression, and other pelvic organ and periph-
ral nerve involvement have all been reported, as have more
istant inﬂammatory and ﬁbrotic complications of the medi-
stinum, pericardium or pleura, and even the thyroid, sinuses,
r orbit, though these are uncommon.4,5 In four of our ﬁve
atients hydronephrosis was a presenting manifestation, in
esemblance to the literature.
Patients 4 and 5 diagnosed with retroperitoneal ﬁbrosis
ased only on PET-CT imaging without biopsy. A few stud-
es showed that retroperitoneal ﬁbrosis can be diagnosed base
nly on PET-CT alone. In 2010, Jansen et al.6 evaluated weather
ET-CT was useful for the diagnosis of retroperitoneal ﬁbro-
is. At baseline, the test was positive in 20/26 of patients 6;5 6(2):101–104 103
with positive predictive value of 0.63. Systematic review pub-
lished in 2013,7 evaluated the role of PET-CT in the diagnosis of
retroperitoneal ﬁbrosis. The authors concluded that the test is
useful in the diagnosis and in evaluating treatment response.
The results of routine laboratory tests are consistent with
inﬂammatory diseases. In a large cohort of 58 patients with
retroperitoneal ﬁbrosis,8 Elevations in acute-phase reactants,
such as ESR and CRP was found in 66.7% and in 64.9%, respec-
tively and in all of our patients. Positive antinuclear antibodies
detected in up to 27% of the cohort and in one patient of this
case series.
IgG4 antibodies are dynamic molecules that can exchange
Fab arms by swapping a heavy chain and attached light chain,
IgG4 can form bispeciﬁc antibodies, as well as functioning as
a monovalent molecule.9
IgG4 predominance in male patients with retroperitoneal
ﬁbrosis was reported recently, like patient 3 of our series.10
IgG4-related disease (IgG4RD) is a novel clinical disease entity
characterized by elevated serum IgG4 concentration tissue
inﬁltration by IgG4-positive plasma cells.
In the absence of randomized trials, the treatment of
idiopathic retroperitoneal ﬁbrosis is empirical. Spontaneous
resolution has been reported in some cases,11 and patients
with indolent disease not affecting adjacent structures might
need only monitoring. However, patients with active disease
usually require medication. Glucocorticoids are the main-
stay of therapy and all our patients received this treatment,
other immunosuppressive drugs (e.g., mycophenolate mofetil,
azathioprine)12 have been used successfully together with
glucocorticoids, but the superiority of these combinations
over glucocorticoids alone is still unproven.13 Tamoxifen has
become an attractive therapeutic option. However, in 2011,
Vaglio et al.14 enrolled 40 patients with newly  diagnosed idio-
pathic retroperitoneal ﬁbrosis in a treatment trial. The 36
patients who achieved remission after induction therapy with
1 mg/kg prednisone daily were randomly assigned to receive
either tapering prednisone (initial dose 0.5 mg/kg daily) or
tamoxifen (ﬁxed dose 0.5 mg/kg daily) for 8 months. Evaluation
at termination of treatment revealed relapse rates of 6% in the
prednisone group and 39% in the tamoxifen group, suggesting
an advantage of prednisone.
Conclusion
We  presented a series of 5 patients with retroperitoneal ﬁbro-
sis. We  emphasize that an abdominal and groin pain with
elevated acute phase reactants should prompt an evaluation
for retroperitoneal ﬁbrosis.
One patient in our series with elevated serum IgG4 level
developed this syndrome after being treated with Etaner-
cept. This is the second report15 published concerned the
development of retroperitoneal ﬁbrosis after TNF inhibitors
treatment, and further studies are needed.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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